🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist




























Forecasts

No ConstituentsNo Constituents

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Standalone Half Yearly Results (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales4.954.108.217.658.164.49109.66
Expenses4.573.006.756.258.744.089.959.33
Interest0.250.320.330.380.410.410.440.07
Operating Profit0.381.101.461.40-0.580.410.370.33
OPM %7.6826.8317.7818.30-7.119.133.593.42
Other Income0.000.000.020.110.220.220.250.00
Depreciation0.110.080.080.080.050.070.030.07
Profit Before Tax0.030.701.081.04-0.820.150.150.19
Tax %33.3321.4336.1125.9625.6120.0033.3321.05
Net Profit0.020.550.690.77-0.610.120.100.15
EPS in Rs

Standalone Profit Loss (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales171211121615
Expenses1611109.741514
Operating Profit0.900.860.772.570.820.79
OPM %5.357.316.8320.905.175.31
Other Income0.010.000.000.020.320.47
Interest0.410.440.510.650.790.85
Depreciation0.310.260.220.170.130.10
Profit Before Tax0.190.160.041.780.230.31
Tax %16.3124.7124.8330.1227.8926.91
Net Profit0.160.120.031.250.160.22
EPS in Rs
Dividend Payout %0.000.000.000.000.000.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital3.303.303.309.951414
Reserves3.944.064.100.738.899.11
Borrowings4.535.525.304.936.832.57
Other Liabilities2.231.010.862.072.732.09
Total Liabilities141414183228
Fixed Assets2.131.871.651.511.381.28
CWIP0.000.000.000.000.001.57
Investments0.000.000.000.000.000.00
Other Assets121212163125
Total Assets141414183228

Standalone Cash Flows (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity-1.46-1.000.21-1.66-5.300.22
Cash from Investing Activity-0.020.000.00-0.030.32-1.11
Cash from Financing Activity1.510.98-0.221.6811-5.10
Net Cash Flow0.03-0.02-0.01-0.006.01-5.99

Shareholdings

Shareholding History

Quarterly
Yearly
Quarterly
Jun 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters90.45%64.52%64.52%64.09%63.89%63.89%63.89%63.65%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public9.55%35.48%35.48%35.91%36.11%36.11%36.11%36.35%
Total Shareholders21659585581551492476462

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

professionalIcon

Upgrade

transaction-premiumtransaction-premium

Projection

No ConstituentsNo Constituents

Documents

Presentations
Concalls
Reports
Presentations

No documents found!

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Vilin Bio Med Ltd

Vilin Bio Med Ltd (VILINBIO) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vilin Bio Med Limited is primarily engaged in manufacturing pharmaceutical products, specializing in both Beta-Lactam and Non-Beta-Lactam medicines. The company boasts a robust portfolio of over 1000 drug approvals across diabetic, neurological, and cardiovascular therapeutic areas. Vilin Bio Med has a state-of-the-art manufacturing facility and R&D foundation in Roorkee, enhancing its product innovation capabilities. The company's recent IPO in 2023 raised Rs 12 Crore, marking a significant step for its financial strategy and growth plans.

Over the past 52 weeks, Vilin Bio Med Ltd has traded between a low of ₹16.50 and a high of ₹38.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vilin Bio Med Ltd has a market capitalization of approximately 48.34. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vilin Bio Med Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 216.56 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 48.34 Cr, Vilin Bio Med Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vilin Bio Med Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vilin Bio Med Ltd is 216.56. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.